Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP) with bullish sentiments.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Veeva Systems (VEEV)
In a report released today, Charles Rhyee from TD Cowen maintained a Buy rating on Veeva Systems, with a price target of $235.00. The company’s shares closed last Thursday at $173.50, close to its 52-week low of $170.25.
According to TipRanks.com, Rhyee is a 4-star analyst with an average return of
Currently, the analyst consensus on Veeva Systems is a Moderate Buy with an average price target of $239.53, which is a 34.0% upside from current levels. In a report issued on May 20, TipRanks – Google also upgraded the stock to Buy with a $183.00 price target.
See the top stocks recommended by analysts >>
Mineralys Therapeutics, Inc. (MLYS)
Goldman Sachs analyst Richard Law CFA maintained a Buy rating on Mineralys Therapeutics, Inc. yesterday and set a price target of $42.00. The company’s shares closed last Thursday at $25.10.
According to TipRanks.com, CFA is a 2-star analyst with an average return of
Currently, the analyst consensus on Mineralys Therapeutics, Inc. is a Strong Buy with an average price target of $51.17, representing a 104.2% upside. In a report issued on June 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $56.00 price target.
ArriVent BioPharma, Inc. (AVBP)
JonesTrading analyst Boris Peaker maintained a Buy rating on ArriVent BioPharma, Inc. today and set a price target of $45.00. The company’s shares closed last Thursday at $29.55.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of
ArriVent BioPharma, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $44.56, representing a 49.6% upside. In a report issued on May 29, Truist Financial also initiated coverage with a Buy rating on the stock with a $45.00 price target.
Read More on VEEV:
